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other inputs came from published literature. RESULTS: When compared to the
average patient population, initiation of ATV/r- or LPV/r-based treatments (with
CD4 cell 200 cells/m3 at baseline) in treatment-naïve patients were cost-effec-
tive strategies resulting in more life-years and quality-adjusted life years (QALYs)
gained, at lower overall costs. Initiation of ATV/r treatment provided greater effec-
tiveness (additional 1.69 life-years and 1.77 QALYs) and lower costs (€162,460 vs.
€177,038; 2010 values) compared with LPV/r (5% discounting for costs and effects).
CONCLUSIONS: Initiating treatment with ARV agents when CD4 cell 200
cells/m3 was predicted to lower overall treatment costs, lead to increased survival
and fewer ADEs. Similarly, initiating treatment with ATV/r rather than LPV/r rep-
resented a cost-effective strategy in treatment naïve patients with HIV-1 infection.
Probabilistic sensitivity analyses were performed and confirmed the robustness of
the base-case findings.
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OBJECTIVES: Candidemia or invasive candidiasis is a nosocomial infection associ-
ated with considerable mortality and with substantial economic impact due to its
long hospital length of stay. The role of appropriate initial antifungal agent is
crucial for improved outcomes and reduced hospital costs. This study evaluated
the cost-effectiveness of anidulafungin as a new echinocandin, by comparing
anidulafungin with fluconazole in the treatment of candidemia or invasive
candidiasis.METHODS:A decision analyticmodel was developed, from the Korean
health care systemperspective, to examine the cost-effectiveness of anidulafungin
compared with fluconazole. Efficacy data on treatment success, renal toxicity, and
survival were obtained from the clinical trial studywhich compared anidulafungin
with fluconazole (Reboli, 2007). Drug cost and othermedical cost were derived from
a cost of illness study of candidemia in Korea. Average cost-effectiveness and
incremental cost-effectiveness of each drug per survival patient were calculated.
RESULTS: The overall survival rate was higher for patients treated with anidula-
fungin than with fluconazole (77.17% vs. 68.64%). The total costs were 6,929,620
KRW for anidulafungin and 6,629,357KRW for fluconazole. However, because of the
better clinical efficacy, the average cost-effectiveness per survival patient was
lower for the anidulafungin treatment than fluconazole treatment (8,980,222 KRW
vs. 9,657,582 KRW). The incremental cost-effectiveness of anidulafungin compared
with fluconazole was estimated to be 3,532,684 KRW. CONCLUSIONS: Anidulafun-
gin indicated better clinical efficacy in managing candidemia or invasive candidi-
asis. Although there is an increase in drug costs, treating candidemia or invasive
candidiasis with anidulafungin is a cost-effectiveness strategy. This study shows
that anidulafungin as first-line therapy can be cost-effectiveness alternative to
fluconazole in candidemia or invasive candidiasis treatment.
PIN39
COST-EFFECTIVENESS ANALYSIS OF LINEZOLID VERSUS VANCOMYCIN IN
PATIENTS WITH SUSPECTED MECHANICAL VENTILATOR-ASSOCIATED
PNEUMONIA IN COLOMBIA
Cortes J1, Molina FJ2, Soto R3, Gutierrez-Ardila MV4, Nuñez SM4
1Universidad Nacional de Colombia, Bogotá, Colombia, 2Clinica Universitaria Bolivariana,
Medellin, Antioquia, Colombia, 3Centro Médico Imbanaco, Cali, Colombia, 4Pfizer Colombia,
Bogota, Cundinamarca, Colombia
OBJECTIVES: Ventilator-associated pneumonia (VAP) is an infection acquired in
hospitals with important clinical and economic implications, which raise morbid-
ity and costswithinNational Health Systems. The aim of this studywas to evaluate
the cost-effectiveness of linezolid versus vancomycin for the empiric treatment of
mechanical ventilator associated pneumonia caused by Methicillin-Resistant
Staphylococcus aureus (VAP-MRSA) from the payer’s perspective in Colombia.
METHODS: A validated decision-tree model was developed to assess the cost-
effectiveness of linezolid (600mg/12hrs) against vancomycin (1gr/12hrs) for a co-
hort of adult patients with VAP-MRSA. The model simulated costs and effective-
ness within a time horizon of 90 days. Outcome measure was defined as life-years
gained (LYG). Clinical efficacy and transition probabilities were collected through a
literature review of published clinical trials and validated by a Colombian Delphi
Panel. The Panel also estimated directmedical resource utilization associated with
VAP-MRSA treatment (drugs, hospitalization, and costs associated with adverse
events: thrombocytopenia or renal failure). Unit costs from Colombian price man-
ual (SOAT) was used; acquisition costs were retrieved from the Colombian official
report (SISMED) and by the Law3470/2011. Incremental cost-effectiveness ratio and
sensitivity analyses for key variableswere performed for testingmodel robustness.
Results were expressed in 2011 US$. RESULTS: Patients treated with linezolid
achieved the highest LYG compared to vancomycin (5.63 vs. 3.40), with a shorter
intensive care unit (ICU) length of stay (12.2 vs. 16.2 days respectively). Overall
treatment costs were lower for linezolid versus vancomycin (US$3356.29 vs.
US$3566.42). Therefore linezolid demonstrated to be a cost-saving alternative,
compared to vancomycin. Likewise, the probability of clinical recovery, death,
switch of antibiotic therapy and daily cost in ICU were the most impactful factors
that affected health net profit without changing above conclusions.
CONCLUSIONS: Linezolid generates savings to the Colombian health system and it
is a cost-saving therapy for treating VAP-MRSA adult patients.
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OBJECTIVES: In 2009, theH1N1 influenza epidemic in theUnited States caused over
19,000 deaths. This study aims to conduct an economic evaluation of the twomost
commonly recommended treatment choices for the H1N1 flu, oseltamivir and
zanamivir. METHODS: A cost effectiveness analysis was performed by evaluating
randomized clinical trials (RCTs) and other published literature for oseltamivir and
zanamivir. Direct medical costs included drug costs, cost of hospitalization, cost
associated with complications and adverse drug events. Effectiveness was as-
sessed using efficacy data from RCTs. All costs were adjusted to 2011 USD using
consumer price index. The primary outcome measures were the duration and
severity of illness in infected patients. A decision tree analysis model was devel-
oped using TreeAge Pro 2009 from aUS third party perspective. Oneway sensitivity
analysis using total cost was conducted to evaluate the robustness of results.
RESULTS: Efficacy of oseltamivir and zanamivir was found to be 69% and 81%,
respectively. Total cost for treating H1N1 patient was higher for oseltamivir ($1878)
compared to zanamivir ($1099). The expected cost of treatment per unit change
was higher for osletamivir ($27.2) compared to zanamivir ($13.6). ICERwas found to
be $64.91 per unit change. Results of one way sensitivity analysis were robust with
results of the decision tree model. CONCLUSIONS: This study provides some pre-
liminary conclusion that zanamivir was more cost effective as compared to osel-
tamivir for treatment of H1N1flu, fromUS third party perspective. Further research
with prospective data may help providers make informed decisions, if such an
epidemic happens again.
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OBJECTIVES: Yellow fever is a haemorrhagic disease caused by arbovirus from the
flavivirus genus. It is a disease that has no cure currently and up to 50% of those
affected may die. According to the reports about 20% of the population may be
affected during a typical outbreak. The only way to prevent the disease is through
vaccination. Although vaccine efficacy is over 95%, neurotropic, viscerotropic and
hypersentivity adverse events following immunization are associated with vacci-
nation. The objective was to assess the cost-effectiveness of vaccination (against
yellow fever) in a country endemic to the yellow fever disease.METHODS: A deci-
sion analytic model using decision tree was employed in this research. The deci-
sion as to whether or not the yellow fever vaccination (among healthy people 10
years or older) should be givenwas characterized. The probability of adverse events
following immunization (AEFIs) and the probability of treatment among vaccinees
were calculated. Among non vaccinees, the probability of an infection with the
yellow fever was calculated. Thesewere done using estimates predominantly from
the literature. Costswere assigned to the various event pathways using the societal
perspective and expected costs of the outcomes were then calculated. RESULTS:
The expected cost for vaccination was less than $1.00 and the expected cost for
non-vaccination was $30.50. Vaccination against yellow fever had a higher effect
than non-vaccination. CONCLUSIONS: Vaccination against yellow fever among
Ghanaians, ten years or olderwas cost-effective. People should be encouraged to go
for the vaccination because the disease is endemic in the region.
PIN42
THE COST-EFFECTIVENESS OF TELAPREVIR (TVR) IN COMBINATION WITH
PEGYLATED INTERFERON-ALFA AND RIBAVIRIN (PR) FOR THE TREATMENT OF
GENOTYPE 1(G1) CHRONIC HEPATITIS C PATIENTS: A POST-HOC ANALYSIS OF
IL-28B SUBGROUP
Curtis S1, Cure S2, Bianic F3, Gavart S4, Dearden L1, Fleischmann J5, Ouwens M6, Lee S7
1Janssen, High Wycombe, UK, 2OptumInsight, Uxbridge, UK, 3i3 Innovus, Uxbridge, Greater
London, UK, 4Janssen Pharmaceutica, Beerse, Belgium, 5Janssen-Cilag Germany, Neuss,
Germany, 6Mapi Values Netherlands, Houten, The Netherlands, 7Janssen Global Services,
Companies of Johnson & Johnson, Horsham, PA, USA
OBJECTIVES: Telaprevir is a new direct acting antiviral for the treatment of G1
hepatitis C virus (HCV) infection. A post-hoc analysis was conducted to evaluate
the cost-effectiveness of patients according to IL-28B subgroups in both treatment
naïve and previously treated G1 chronic HCV patients. Cost-effectiveness is con-
sidered in terms of incremental cost per quality-adjusted life-year (QALY) gained
from the perspective of the NHS in England and Wales. METHODS: Two Markov-
models were developed to evaluate treatments studied in TVR phase III clinical
trials: TVR response-guided therapy of 12 weeks of TVR with PR [24 weeks PR for
patients achieving an extended rapid viral response (eRVR), 48 weeks of PR for
patients not achieving an eRVR] for treatment-naïve patients; 12 weeks of TVR in
combination with 48 weeks of PR therapy for treatment-experienced patients. IL-
28B datawas available for 140 and 161 T12/PR and PBO/PR patients, equating to 39%
and 45% of all T12/PR and PBO/PR patients in ADVANCE, respectively. IL-28B geno-
type data was available for 212 and 105 T12/PR and PBO/PR patients, equating to
80% of all patients in both treatment arms in REALIZE. Among T12/PR patients the
CC, CT and TT distribution was 19%, 63% and 17% respectively; among PBO/PR
patients the distribution was 16%, 55% and 29% respectively. RESULTS: TVR based
therapy was cost-effective when compared to PBO/PR regimen in both treatment-
naïve and experienced patients regardless of IL-28B subtypes (CC, CT, and TT).
CONCLUSIONS: The introduction of telaprevir to current standard of care for HCV
genotype 1 patients is clinicallymore efficacious than PR alone and cost-effective at
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the £20,000 and £30,000 willingness-to-pay thresholds for both treatment-naïve
patients and treatment-experienced patients regardless of IL-28B subtypes.
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OBJECTIVES: Develop an economic evaluation of regimes Tenofovir/Emtricitabina
(Truvada
®
)EFV versus TDFFTCLPV/r, ABC3TCEFV, ABC3TCLPV/r,
ZDV3TCEFV in naïve patients infected with HIV through a cost-effectiveness
study from the public health system Mexican perspective. METHODS: We devel-
oped an economic Markov model to compare information on the effectiveness,
utility and costs of the use of Tenofovir/Emtricitabina (Truvada
®
)EFV versus
TDFFTCLPV/r, ABC3TCEFV, ABC3TCLPV/r, ZDV3TCEFV over a 2 year
period with six-month cicles. Efficacy was measured by the percentage of individ-
uals with plasmaHIV RNA 50 copies/mL and Qalys, based on a systematic review
and meta-analysis of clinical trial of regimens in treatment-naïve populations.
Model follows the recommendations of antiretroviral persons handling Guide with
HIV in Mexico (2010 SSA). The direct costs, treatment of adverse events, cost of
failure of the treatment and costs of medical attention of HIV were estimated and
were obtained from the mexican public health institutions. All costs were calcu-
lated in 2011 mexican pesos (MXP). Incremental cost effectiveness ratios were
expressed as cost per 1% of individuals with plama HIV RNA50 copies/ML and
Qalys. Costs and outcomes were discounted at 5%. Probabilistic sensitivity analy-
ses viaMonte Carlo simulations and a budget impact analysis (BIA) were perfomed.
RESULTS:Tenofovir/Emtricitabina (Truvada
®
)EFVwasmost effective than others
comparators with a probability of 0.562 HIV RNA 50 copies/mL and 1.614 Qalys.
Tenofovir/Emtricitabina (Truvada
®
)EFV resulted as the alternative with less av-
erage total cost per patients ($91,439.77). Tenofovir/Emtricitabina (Truvada®)EFV
is a dominant option and cost saving compared to the alternatives. Deterministic
probabilistic sensitivity analysis showed that the findings are robust. The analysis
of BIA show that public health system mexican could save about $140,480,959 if
they use Tenofovir/Emtricitabina (Truvada®)EFV rather than other options in
these patients. CONCLUSIONS: Tenofovir/Emtricitabina (Truvada®)EFV is an ef-
ficient and cost-saving drug on 96 weeks for the treatment of adult naïve patients
with HIV infection in Mexico.
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OBJECTIVES:What happens when technologies leave Randomized Controlled Tri-
als and approach the real world? Sometimes no answers are provided to this ques-
tion. The aim of the COALA study was to evaluate, taking the Italian NHS (payer)
perspective, the lifetime cost-utility of lopinavir/ritonavir vs. atazanavir  ritona-
vir, with a tenofovir-emtricitabine backbone, in a sample of 319 naïve patients
starting from, and developing, the assumptions of the Broder (2011) Markovmicro-
simulationmodel.METHODS: The health andmonetary outcomes associated with
ATVr and LPV/r regimens, were analyzed considering: 8 health states, incidence
of diarrhea and/or hyperbilirubinemia, AIDS events, opportunistic infections, and
CHD events and, for the first time in an economic evaluation concerning HIV
patients, CKD. Patients were enrolled in one of two scenarios: LPV/r or ATVr
(ATV1), and followed first or second line treatment. The two lines were both mod-
elled at an individual patient level. A sensitivity analysis regarding ATVr arm
(ATV2) was assessed, in order to replicate the results of the CASTLE trial study, and
to compare them with an ATV1 arm. The total cost per patient was calculated
considering drugs costs, clinical effectiveness data, as well as institutional guide-
lines, protocols and the Lombardy Region reimbursement tariffs. RESULTS: LPV
was assessedwith a gain in terms ofQALY equal to 0.150 to 0.447. Themodel results
show a higher incidence of cardiovascular events (6.5 per 1,000 inhabitants) for the
LPV arm, and a lower incidence of CKD (27.1 vs. 110.9-135.3) for LPV.
CONCLUSIONS: Considering the economic performance, there was an annual eco-
nomic per capita advantage between €73 and €138. This, in terms of QALY and
reduction of costs, reveals that LPV/r treatment gives a higher economical perfor-
mance and is more cost-effective compared with ATVr.
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OBJECTIVES: Poor adherence to HIV antiretroviral therapies (ART) increases the
risk of incomplete viral suppression, development of viral resistance, progression
to acquired immune deficiency syndrome, and death. However, there is little un-
derstanding of the impact of specific treatment-related adverse events (AEs) on
adherence. This meta-analysis was conducted to assess the effects of treatment-
related AEs on adherence to ART in adult HIV-infected patients. METHODS: A
systematic review of studies involving HIV-infected patients aged 16 years and
reporting an odds ratio (OR) for factors affecting adherence to ART was conducted.
Embase and MEDLINE databases were searched between 1996 and 2010. Bibliogra-
phies of identified review papers were also searched. Studies conducted in popu-
lations limited to a particular demographic characteristic or behavioral risk factor
were excluded. To qualify for inclusion into the meta-analysis, treatment-related
AEs had to be defined similarly across studies. Multiple ORs from the same study
were included where study sub-groups were distinct. Random effects models were
used to pool ORs. RESULTS: Nineteen studies and 18 ART-related AEs were in-
cluded in the analysis. Adherence to ART was significantly lower in patients with
non-specific AEs than in patientswho did not experience anyAEs (OR0.62; 95%CI:
0.46-0.83). Patients with specific AEs such as cough (OR0.65; 0.53-0.79), fatigue
(OR0.63; 0.43-0.92), confusion (OR0.35; 0.18-0.66), anxiety (OR0.63; 0.41-0.95),
taste disturbances (OR0.49; 0.30-0.77), nausea (OR0.57; 0.43-0.77), and loss of
appetite (OR0.54; 0.32-0.93) were significantly less likely to adhere to ART com-
pared to patients without these AEs. Diarrhea, insomnia, sexual dysfunction, lip-
odystrophy, numbness, pain when swallowing, tingling in mouth/tongue, derma-
tological conditions, abdominal pain, and vomiting were not significantly
associated with adherence, although trends toward decreased adherence were
observed. CONCLUSIONS: Specific treatment-related AEs can significantly de-
crease adherence to ART. Knowledge of these effects may allow for targeted man-
agement of AEs to improve ART adherence and clinical outcomes.
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OBJECTIVES: The standard of care for hepatitis C (ribavirin and peginterferon) has
been found to be associated with an increased risk of anemia. The objective of this
study was to investigate the effect anemia has on health status and work produc-
tivity among patients currently treated for hepatitis C. METHODS: Data from the
2011 U.S. National Health and Wellness Surveys were used. Among respondents
who were currently or had formerly been treated for hepatitis C, those with and
without a diagnosis of anemia were compared on health status (using the SF-12v2)
andwork productivity (using theWPAI questionnaire) using general linearmodels.
Demographics, health behaviors, and comorbidities were also measured and in-
cluded as covariates. RESULTS: A total of 305 patients were currently or formerly
treated for hepatitis C. Of these patients, 22 reported having been diagnosed with
anemia (7.21%). The presence of anemia was associated with significantly lower
mental component summary scores (Mean37.00 vs. Mean45.21) and worse
health utilities (Mean0.53 vs. Mean0.67) (all ps.05). Impairment in daily activ-
ities was significantly higher among those with anemia (Mean65.00% vs.
Mean39.33%, p.05). Fewpatientswere currently employed (n7with anemia vs.
n121 without anemia), however, absenteeism (Mean34.00% vs. Mean5.79%),
presenteeism (Mean51.43% vs. Mean23.67%), and overall work impairment
(Mean61.00% vs. 25.98%) were all significantly higher among those with anemia
(all ps.05). The health status and activity impairment differences remained after
controlling for age, gender, ethnicity, smoking and theCharlson comorbidity index.
CONCLUSIONS: These results suggest that presence of anemia is associated with a
substantial humanistic and indirect cost burden among patients who are treated
for hepatitis C. Novel treatments which reduce the rate of anemia may result in a
substantial improvement in patient outcomes.
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OBJECTIVES: Although prior studies have examined the burden of hepatitis C
(HCV) within individual countries, no study has compared the burden across coun-
tries using a consistent methodology. The aim of this study was to quantify the
burden of HCV in the United States (US), France, Germany, Italy, Spain, the UK,
China, and Japan.METHODS: The 2010 5EU (N57,805), 2009 US (N75,000), 2008/
2009 Japan (N37,683), and 2009/2010 urban China (N33,261) waves of the Na-
tional Health andWellness Survey were used as data source. Within each country,
patients with a self-reported diagnosis of HCV were compared with those who did
not report a diagnosis of HCV on sociodemographics, health behaviors, comorbidi-
ties, and health outcomes (health status using the SF-12v2,work productivity using
the WPAI, and healthcare resource use in the past six months). The effect of HCV
was examined using regression analysis applying samplingweights. RESULTS:The
prevalence of HCV ranged from 0.26% (China) to 1.42% (Italy). Patients in Japan and
Italy (61.60 and 61.02 years, respectively) were the oldest, while patients in the US
were the most likely to be obese (39.31%) and have concomitant anxiety (38.43%)
and depression (46.05%) compared with other countries. Pooling countries and
adjusting for sociodemographics, health behaviors, and comorbidities, HCV was
associated with significantly lower physical component summary scores (b-2.51)
and health utilities (b-0.04) and greater overall work impairment (b8.79), physi-
cian visits (b2.91), and emergency department visits (b0.30) (all ps.05). The
effects on health status were strongest in the US and UK while the effects on
healthcare resource use were strongest in Japan. CONCLUSIONS: HCV was associ-
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